Immunic, Inc. (IMUX)
NASDAQ: IMUX · IEX Real-Time Price · USD
1.150
+0.030 (2.68%)
At close: Jul 2, 2024, 4:00 PM
1.120
-0.030 (-2.61%)
After-hours: Jul 2, 2024, 6:13 PM EDT
Immunic Stock Forecast
IMUX's stock price has decreased by -50.64% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Immunic stock have an average target of 8.50, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 639.13% from the current stock price of 1.15.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 5, 2024.
Analyst Ratings
The average analyst rating for Immunic stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +769.57% | Apr 5, 2024 |
| Wedbush | Wedbush | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +508.70% | Oct 10, 2023 |
| Wedbush | Wedbush | Buy Reiterates $5 | Buy | Reiterates | $5 | +334.78% | Jul 27, 2023 |
| Wedbush | Wedbush | Buy Initiates $5 | Buy | Initiates | $5 | +334.78% | Jan 31, 2023 |
| SVB Leerink | SVB Leerink | Buy → Hold Downgrades $9 → $5 | Buy → Hold | Downgrades | $9 → $5 | +334.78% | Oct 21, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.03
from -2.11
EPS Next Year
-0.86
from -1.03
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 734.9M | 1.1B | 1.5B |
| Avg | n/a | n/a | 357.0M | 269.6M | 591.9M |
| Low | n/a | n/a | n/a | n/a | 44.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 210.1% | 453.5% |
| Avg | - | - | - | -24.5% | 119.6% |
| Low | - | - | - | - | -83.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.00 | -0.76 | 5.37 | 6.65 | 9.89 |
| Avg | -1.03 | -0.86 | 1.15 | 2.67 | 4.39 |
| Low | -1.05 | -0.89 | -1.01 | -1.07 | -0.80 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 478.4% | 270.1% |
| Avg | - | - | - | 132.5% | 64.1% |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.